Pharmacogenetics/pharmacogenomics and antirheumatic drugs in rheumatology

Pharmacogenomics

Volumn 5, Issue 8, 2004, Pages 1107-1116

  Ferracioli, Gianfranco ^a   De Santis, Maria ^a   Tolusso, Barbara ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

Azathioprine; COXIBs; Cyclophosphamide; Leflunomide; Methotrexate; NSAIDs; Pharmacogenetic; Pharmacogenomics; Rituxan; SNP; TNF blockers

Indexed keywords

ACETYLSALICYLIC ACID; ANTIRHEUMATIC AGENT; AZATHIOPRINE; CYCLOOXYGENASE 2 INHIBITOR; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; ETANERCEPT; FLUOXETINE; IBUPROFEN; IMIPRAMINE; INFLIXIMAB; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; LEFLUNOMIDE; MERCAPTOPURINE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PHENYTOIN; PIROXICAM; RIFAMPICIN; RITUXIMAB; SALAZOSULFAPYRIDINE; TACROLIMUS; TENOXICAM; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNINDEXED DRUG; VERAPAMIL; WARFARIN;

AUTOIMMUNE DISEASE; BEHAVIOR; BLEEDING; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; CLINICAL TRIAL; COMORBIDITY; DRUG COST; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG RESPONSE; ENVIRONMENTAL FACTOR; GENE INTERACTION; GENOTYPE; HUMAN; HYPERTENSION; INDIVIDUALIZATION; KIDNEY FAILURE; NEPHROTOXICITY; NONHUMAN; OVARY INSUFFICIENCY; PATIENT COMPLIANCE; PATIENT MONITORING; PHARMACOGENETICS; PHARMACOGENOMICS; PRESCRIPTION; REVIEW; RHEUMATIC DISEASE; RHEUMATOLOGY; SYMPTOMATOLOGY;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIRHEUMATIC AGENTS; CYCLOOXYGENASE INHIBITORS; HUMANS; PHARMACOGENETICS; RHEUMATIC DISEASES; RHEUMATOLOGY;

EID: 11044229099     PISSN: 14622416     EISSN: None     Source Type: Journal    
DOI: 10.1517/14622416.5.8.1107     Document Type: Review

References (72)

1. Shah J: Criteria influencing the clinical uptake of pharmacogenomic strategies. Br. Med. J. 328, 1482-1486 (2004).
2. Bates DW, Cullen DJ, Laird N et al.: Incidence of adverse drug events and potential adverse drug events: implications for prevention. JAMA 274, 29-34 (1995).
3. Classen DC, Pestotnik SL, Evans RS, Burke JR: Computerized surveillance of adverse drug events in hospital patients. JAMA 266, 2847-2851 (1991).
4. Gurwitz JH, Field TS, Harrold LR et al.: Incidence and preventability of adverse drug events among older persons in the ambulatory setting. JAMA 289, 1107-1116 (2003).
5. Phillips KA, Veenstra DL, Oren E, Lee JK, Sadee W: Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review. JAMA 286, 2270-2279 (2001).
6. Haga SB, Burke W: Using pharmacogenetics to improve drug safety and efficacy. JAMA 291, 2869-2871 (2004).
7. Olsen NJ, Stein CM: New drugs for rheumatoid arthritis. N. Engl. J. Med. 350, 2167-2179 (2004).
8. Tsokos GC: B cells, be gone: B cell depletion in the treatment of rheumatoid arthritis. N. Engl. J. Med. 350, 2546-2548 (2004).
9. Kalow W. Pharmacogenetics, pharmacogenomics and pharmacobiology. Clin. Pharmacol. Ther. 70, 1-4 (2001).
10. Katz DA: From bench to bedside: a diagnostic framework for pharmacogenetics research. Mol. Genet. Metab. 77, 57-60 (2002).
11. Dressman MA, Malinowski R, McLean LA et al.: Correlation of major cytognetic response with a pharmacogenetic marker in chronic myeloid leukemia patients treated with imatinib (ST1571). Clin. Cancer Res. 10, 2265-2271 (2004).
12. Huskisson EC, Woolf DL, Balme HW, Scott J, Franklin S: Four new anti-inflammatory drugs: responses an variations. Br. Med. J. 1(6017), 1048-1049 (1976).
13. Vianna-Jorge R, Perini JA, Rondinelli E, Suarez-Kurtz G: CYP2C9 genotypes and the pharmacokinetics of tenoxicam in Brazilians. Clin. Pharmacol. Ther. 76, 18-26 (2004).
14. Halushka MK, Walker LP, Halushka PV: Genetic variation in cyclooxygenase-1: effects on response to aspirin. Clin. Pharmacol. Ther. 73, 122-130 (2003).
15. Fritsche E, Baek SJ, King LM, Zeldin DC, Eling TE, Bell DA: Functional characterization of cyclooxygenase-2 polymorphism. J. Pharmacol. Exp. Ther. 299, 468-476 (2001).
16. Cipollone F, Toniato E, Martinotti S et al.: A polymorphism in the cyclooxygenase-2 gene as an inherited protective factor against myocardial infarction and stroke. JAMA 291, 2221-2228 (2004).
17. Hayslett JP, Kashgarian M, Cook CD, Spargo BH: The effect of azathioprine on lupus glomerulonephritis. Medicine 51, 393-412 (1972).
18. Urowitz MB, Gordon DA, Smythe HA, Pruzanski W, Ogryzlo MA: Azathioprine in rheumatoid arthritis. A double-blind, cross over study. Arthritis Rheum. 16, 411-418 (1973).
19. Krynetski EY, Evans WE: Genetic polymorphism of thiopurine S-methyltransferase: molecular mechanism and clinical importance. Pharmacology 61, 136-146 (2000).
20. Colombel JF, Ferrari N, Debuysere H et al.: Genotypic analysis of thiopurine methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy. Gastroenterology 118, 1025-1030 (2000).
21. Marinaki AM, Ansari A, Duley JA, Arenas M, Sumi S, Lewis CM: Adverse drug relations to azathioprine therapy are associated with polymorphism in the gene encoding inosine triphosphate pyrophosphatase (ITPase). Pharmacogenetics 14, 181-187 (2004).
22. Cameron JS: Lupus nephritis. J. Am. Soc. Nephrol. 10, 413-424 (1999).
23. Takada K, Arefayene M, Desta Z et al.: Cytochrome P450 pharmacogenetics as a predictor of toxicity and clinical response to pulse cyclophosphamide in lupus nephritis. Arthritis Rheum. 50, 2202-2210 (2004).
24. Contreras G, Pardo V, Leclerc B et al.: Sequential therapies for proliferative lupus nephritis. N. Engl. J. Med. 350, 971-980 (2004).
25. Dall'Era M, Davis J: CTLA4Ig: a novel inhibitor of costimulation. Lupus 13, 372-376 (2004).
26. Daikh DI, Wofsy D: Cutting edge. Reversal of murine lupus nephritis with CTLA4Ig and cyclophosphamide. J. Immunol. 166, 2913-2916 (2001).
27. Anolik J, Sanz I, Looney RJ: B cell depletion therapy in systemic lupus erythematosus. Curr. Rheumatol. Rep. 5, 350-356 (2003).
28. Sabbagh N, Delaporte E, Marez D, LoGiudice JM, Piette F, Broly F: NAT2 genotyping and efficacy of sulfasalazine in patients with chronic discoid lupus erythematosus. Pharmacogenetics 7, 131-135 (1997).
29. Ricart E, Taylor WR, Loftus EV et al.: N-Acetyltransferase 1 and 2 genotypes do not predict response or toxicity to mesalamine and sulfasalazine in patients with ulcerative colitis. Am. J. Gastroenterol. 97, 1763-1768 (2002).
30. Kumagai S, Komada F, Kita T et al.: N-Acetyltransferase 2 genotype - related efficacy of sulfasalazine in patients with rheumatoid arthritis. Pharm. Res. 21, 324-329 (2004).
31. Wadelius M, Stjenberg E, Wiholm BE, Rane A: Polymorphism of NAT2 in relation to sulphasalazine-induced agranulocytosis. Pharmacogenetics 10, 35-41 (2000).
32. Tanaka E, Taniguchi A, Urano W et al.: Adverse effects of sulphasalazine in patients with rheumatoid arthritis are associated with diplotype configuration of the N-acetyltransferase 2 gene. J. Rheumatol. 29, 2492-2499 (2002).
33. Pawlik A, Ostanek L, Brzosko I, Gawroska-Szklarz B, Brzosko M, Dakraboska-Zamicin E: Increased genotype frequency of N-acetyltransferase 2 slow acetylation in patients with rheumatoid arthritis. Clin. Pharmacol. Ther. 72, 319-325 (2002).
34. Smolen JS, Kalden JR, Scott DL et al.: Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomized, multicenter trial. European Leflunomide Study Group. Lancet 23, 259-266 (1999).
35. Breedveld FC: Is there a place for leflunomide in the treatment of rheumatoid arthritis? Lancet 358, 1198-1200 (2001).
36. Higashi MK, Veenstra DL, Kondo LM et al.: Association between CYP2C9 genetic variants and anticoagulation-related outcomes durino warfarin therapy. JAMA 287, 1690-1698 (2002).
37. Busaschina A, Schnuelle P, Van Der Woude FJ: Cyclosporin nephrotoxicity. Transplant. Proc. 36(Suppl. 2), S229-S233 (2004).
38. Kelly PA, Wang H, Napoli KL, Kahan BD, Strobel HW. Metabolism of cyclosporin by cytochrome P450 3A9 and 3A4. Eur. J. Drug Metabol, Pharmacokinet. 24, 321-328 (1999)
39. Klotz U: Pharmacological comparison of the statins. Arzneimittelforschung 53, 605-611 (2003).
40. Tang C, Shou M, Mei Q, Rushmore TH, Rodriguez AD: Major role of human liver microsomal cytochrome P450 2C9 (CYP2C9) in the oxidative metabolism of celecoxib, a novel cyclooxygenase-II inhibitor. J. Pharmacol. Exp. Ther. 293, 453-459 (2000).
41. Xie HG, Wood AJ, Kim RB, Stein CM, Wilkinson GR: Genetic variability in CYP3A5 and its possible consequences. Pharmacogenomics 5, 243-272 (2004).
42. McCarey DW, Capell HA, Madhok R: Tacrolimus therapy in rheumatoid arthritis. Rheumatology 43, 946-948 (2004).
43. Weinblatt ME, Coblyn JS, Fox DA et al.: Efficacy of low dose methotrexate in rheumatoid arthritis. N. Engl. J. Med. 312, 818-822 (1985).
44. Lipsky PE, Van Der Hejide DM et al.: Infliximab and methotrexate in the treatment of rheumatoid arthritis. AntiTumor Necrosis Factor Trial in rheumatoid arthritis with concomitant therapy study group. N. Engl. J. Med. 343, 1594-1602 (2000).
45. Bathon JM, Martin RW, Fleishmann RM et al.: A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N. Engl. J. Med. 343, 1586-1593 (2000).
46. Kremer JM, Phelps CT: Long-term prospective study of the use of methotrexate in the treatment of rheumatoid arthritis. Update after a mean of 90 months. Arthritis Rheum. 35, 138-145 (1992).
47. Alarcon GS, Tracy IC, Blackburn WD: Methotrexate in rheumatoid arthritis. Toxic effects as the major factor in limiting long-term treatment. Arthritis Rheum. 32, 671-676 (1989).
48. Vaan Ede AE, Laan RF, Blom HJ, DE Abreu RA, Van De Putte LB: Methotrexate in rheumatoid arthritis: an update with focus on mechanisms involved in toxicity. Semin. Arthritis Rheum. 27, 277-292 (1998).
49. Chen Z, Karaplis AC, Ackerman SL et al.: Mice deficient in methylenetetrahydrofolate reductase exhibit hyperhomocysteinemia and decreased methylation capacity, with neuropathology and aortic lipid deposition. Hum. Mol. Genet. 10, 433-443 (2001).
50. Ulrich CM, Yasui Y, Storb R et al.: Pharmacogenetics of methotrexate: toxicity among marrow transplantation patients varies with the methylenetetrahydrofolate reductase C677T polymorphism. Blood 98, 231-234 (2001).
51. Van Ede AE, Laan RFJM, Blom HJ et al.: The C677T mutation in the methylenetetrahydrofolate reductase gene: a genetic risk factor for methotrexate-related elevation of liver enzymes in rheumatoid arthritis patients. Arthritis Rheum. 44, 2525-2530 (2001).
52. Urano W, Taniguchi A, Yamanaka H et al.: Polymorphisms in the methylenetetrahydrofolate reductase gene were associated with both the efficacy and toxicity of methotrexate used for the treatment of rheumatoid arthritis, as evidenced by single locus and haplotype analysis. Pharmacogenetics 12, 183-190 (2002).
53. Fabris M, Tolusso B, Di Poi E, Assaloni R, Sinigaglia L, Ferraccioli GF: Tumor necrosis factor a receptor gene polymorphism in patients from southern Europe with mild-moderate and severe rheumatoid arthritis. J. Rheumatol. 29, 1847-1850 (2002).
54. Mugnier B, Balandraud N, Darque A, Roudier C, Roudier J, Reviron D: Polymorphism at position -308 of the tumor necrosis factor a gene influences outcome of infliximab therapy in rheumatoid arthritis. Arthritis Rheum. 48, 1849-1852 (2003).
55. Martinez A, Salido M, Bonilla G et al.: Association of the major histocompatibility complex with response to infliximab therapy in rheumatoid arthritis. Arthritis Rheum. 50, 1077-1082 (2004).
56. Criswell LA, Lum RF, Turner KN et al.: The influence of genetic variation in the HLA-DRb1 and LTA-TNF-α regions in the response to treatment rheumatoid arthritis with methotrexate or etanercept. Arthritis Rheum. 50, 2750-2756 (2004).
57. Padyukov L, Lampa J, Heimburger M et al.: Genetic markers for the efficacy of tumor necrosis factor blocking therapy in rheumatoid arthritis. Ann. Rheum. Dis. 62, 526-529 (2003).
58. Bridges SL: Genetic markers of treatment response in rheumatoid arthritis. Arthritis Rheum. 50, 1019-1022 (2004).
59. + cells by rituximab. Blood 101, 1071-1079 (2003).
60. De Vita S, Zaja F, Sacco S, De Candia A, Fanin R, Ferraccioli G: Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis: evidence for a pathogenetic role of B cells. Arthritis Rheum. 46, 2029-2033 (2002).
61. Edwards JC, Szczepanski L, Szechinski J et al.: Efficacy of B cell targeted therapy with rituximab in patients with rheumatoid arthritis. N. Engl. J. Med. 350, 2572-2581 (2004).
62. Pedersen IM, Buhl AM, Clausen P, Geisler CH, Jurlander J: The chimeric antiCD20 antibody rituximab induces apoptosis in B cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction. Blood 99, 1314-1319 (2002).
63. Golay J, Lazzari M, Facchinetti V et al.: CD20 levels determine the in vitro susceptibility to rituximab and complement of B cell chronic lymphocytic leukemia: further regulation by CD55 and CD59. Blood 98, 3383-3389 (2001).
64. Koene HR, Kleijer M, Algra J, Roos D, Von den Borne AE, de Haas M: Fc γ RIIIa-158 V/F polymorphism influences the binding of IgG by natural killer cell Fc γ RIIIa, independently of the Fc γ RIIIa-48 L/R/H phenotype. Blood 90, 1109-1114 (1997).
65. Cartron G, Dacheux L, Salles G et al.: Therapeutic activity of humanized antiCD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgRIIIa gene. Blood 99, 754-758 (2002).
66. Farag SS, Flinn IW, Modali R, Lehman TA, Young D, Byrd JC: FcgRIIIa and FcgRIIa polymorphisms do not predict response to rituximab in B cell chronic lymphocytic leukemia. Blood 103, 1472-1474 (2004).
67. Urano W, Taniguchi A, Yamanaca H et al.: Polymorphism of the methylene tetrahydrofolate reductase gene were associated with both the efficacy and toxicity of methotrexate used for the treatment of rheumatoid arthritis as evidenced by single locus and haplotype analysis. Pharmacogenetics 12, 183-190 (2002).
68. McLeod HL, Evans WE: Pharmacogenomics: unlocking the human genome for better drug therapy. Pharmacol. Toxicol. 41, 101-121 (2001).
69. Bell J: Predicting disease using genomics. Nature 429, 453-456 (2004).
70. Smolen JS, Steiner G: Therapeutic strategies for rheumatoid arthritis. Nat. Rev. Drug Discov. 2, 473-488 (2003).
71. Ferraccioli G: The possible clinical application of pharmacogenetics in rheumatology. J. Rheumatol. 30, 2517-2520 (2003).
72. Evans WE, Relling MV. Moving towards individualized medicine with pharmacogenomics. Nature 429, 464-468 (2004).